Cargando…

A novel NHEJ gene signature based model for risk stratification and prognosis prediction in hepatocellular carcinoma

BACKGROUND: Non-homologous DNA end joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in human. However, the relationship between NHEJ pathway and hepatocellular carcinoma (HCC) is unclear. We aimed to explore the potential prognostic role of NHEJ genes and to develop an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zhu, Huang, Zhenkun, Shi, Yunxing, Yuan, Yichuan, Niu, Yi, Li, Binkui, Yuan, Yunfei, Qiu, Jiliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071660/ https://www.ncbi.nlm.nih.gov/pubmed/37016451 http://dx.doi.org/10.1186/s12935-023-02907-9

Ejemplares similares

Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma
por: Li, Keren, et al.
Publicado: (2023)

TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
por: Yuan, Yichuan, et al.
Publicado: (2023)

S100A9 Derived from Chemoembolization‐Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression
por: Zhong, Chengrui, et al.
Publicado: (2022)

SNRPC promotes hepatocellular carcinoma cell motility by inducing epithelial‐mesenchymal transition
por: Zhang, Yuanping, et al.
Publicado: (2021)

METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition
por: Bi, Fangfang, et al.
Publicado: (2023)

NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3
por: Zhang, Yuanping, et al.
Publicado: (2022)

Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma
por: Liao, Yadi, et al.
Publicado: (2020)

Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
por: Wang, Chenwei, et al.
Publicado: (2021)

Correction to: Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
por: Wang, Chenwei, et al.
Publicado: (2022)

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
por: Li, Binkui, et al.
Publicado: (2021)

Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma
por: Qiu, Jiliang, et al.
Publicado: (2011)

Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study
por: He, Wei, et al.
Publicado: (2020)

PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
por: Shi, Yunxing, et al.
Publicado: (2023)

Novel Hypoxia-Related Gene Signature for Risk Stratification and Prognosis in Hepatocellular Carcinoma
por: Li, Quanxiao, et al.
Publicado: (2021)

Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis
por: Liu, Wenwu, et al.
Publicado: (2019)

Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study
por: Liu, Wenwu, et al.
Publicado: (2019)

Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study
por: Zeng, Qing-An, et al.
Publicado: (2012)

XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
por: Yang, Sitian, et al.
Publicado: (2017)

A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma
por: Sun, Jianping, et al.
Publicado: (2023)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study
por: He, Wei, et al.
Publicado: (2018)

The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis
por: He, Wei, et al.
Publicado: (2015)

A Nucleotide Metabolism-Related Gene Signature for Risk Stratification and Prognosis Prediction in Hepatocellular Carcinoma Based on an Integrated Transcriptomics and Metabolomics Approach
por: Wei, Tianfu, et al.
Publicado: (2023)

An Apoptotic Gene Signature for the Prognosis of Hepatocellular Carcinoma
por: Chen, Kunlun, et al.
Publicado: (2021)

A novel tumor 4-driver gene signature for the prognosis of hepatocellular carcinoma
por: Guo, Houtian, et al.
Publicado: (2023)

A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma
por: Zhou, Taicheng, et al.
Publicado: (2020)

A novel immune signature to predict the prognosis of patients with hepatocellular carcinoma
por: Li, Qinghe, et al.
Publicado: (2021)

A Novel Five-Gene Signature for Prognosis Prediction in Hepatocellular Carcinoma
por: Su, Lisa, et al.
Publicado: (2021)

Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?
por: Li, Binkui, et al.
Publicado: (2010)

A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients
por: Yuan, Jingsheng, et al.
Publicado: (2022)

Identification of a Novel Metastasis-Related miRNAs-Based Signature for Predicting the Prognosis of Hepatocellular Carcinoma
por: Chen, Yuan, et al.
Publicado: (2021)

A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma
por: Zhang, Genhao, et al.
Publicado: (2022)

Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation
por: Liu, Wenwu, et al.
Publicado: (2018)

A novel immune-related gene signature predicts the prognosis of hepatocellular carcinoma
por: He, Shujiao, et al.
Publicado: (2022)

A Novel Purine and Uric Metabolism Signature Predicting the Prognosis of Hepatocellular Carcinoma
por: Yang, Shengjie, et al.
Publicado: (2022)

Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence
por: Tao, Qiang, et al.
Publicado: (2018)

A necroptosis-related gene signature to predict prognosis and immune features in hepatocellular carcinoma
por: Zhang, Kai, et al.
Publicado: (2023)

Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma
por: Chen, Yi, et al.
Publicado: (2022)

A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma
por: Bu, Xiaoyun, et al.
Publicado: (2022)

Novel immune‐related signature for risk stratification and prognosis in prostatic adenocarcinoma
por: Zhao, Hai‐Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fp3moparqu0q7a4nc9c0qm99s9